These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
441 related articles for article (PubMed ID: 33098622)
1. The respiratory impact of novel therapies for spinal muscular atrophy. Paul GR; Gushue C; Kotha K; Shell R Pediatr Pulmonol; 2021 Apr; 56(4):721-728. PubMed ID: 33098622 [TBL] [Abstract][Full Text] [Related]
2. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1. Bischof M; Lorenzi M; Lee J; Druyts E; Balijepalli C; Dabbous O Curr Med Res Opin; 2021 Oct; 37(10):1719-1730. PubMed ID: 34236007 [TBL] [Abstract][Full Text] [Related]
3. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison. Ribero VA; Daigl M; Martí Y; Gorni K; Evans R; Scott DA; Mahajan A; Abrams KR; Hawkins N J Comp Eff Res; 2022 Apr; 11(5):347-370. PubMed ID: 35040693 [No Abstract] [Full Text] [Related]
4. Switching therapies: safety profile of Onasemnogene abeparvovec-xioi in a SMA1 patient previously treated with Risdiplam. Tosi M; Catteruccia M; Cherchi C; Mizzoni I; D'Amico A Acta Myol; 2022; 41(3):117-120. PubMed ID: 36349185 [TBL] [Abstract][Full Text] [Related]
5. Onasemnogene abeparvovec-xioi: a gene replacement strategy for the treatment of infants diagnosed with spinal muscular atrophy. Schwartz M; Likhite S; Meyer K Drugs Today (Barc); 2021 Jun; 57(6):387-399. PubMed ID: 34151905 [TBL] [Abstract][Full Text] [Related]
7. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis. Toro W; Yang M; Georgieva M; Song W; Patel A; Jiang AX; Zhao A; LaMarca N; Dabbous O Adv Ther; 2023 Oct; 40(10):4589-4605. PubMed ID: 37587305 [TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Onasemnogene Abeparvovec Compared With Nusinersen and Risdiplam in Patients With Spinal Muscular Atrophy Type 1 in Brazil: Custo-Efetividade do Onasemnogeno Abeparvoveque (AVXS-101) em Comparação ao Nusinersena e Risdiplam em Pacientes com Atrofia Muscular Espinhal Tipo 1 no Brasil. Fernandes BD; D'Athayde Rodrigues F; Cardoso Cirilo HN; Borges SS; Krug BC; Probst LF; Zimmermann I Value Health Reg Issues; 2024 Mar; 40():108-117. PubMed ID: 38181723 [TBL] [Abstract][Full Text] [Related]
9. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data. Erdos J; Wild C Eur J Paediatr Neurol; 2022 Jul; 39():1-10. PubMed ID: 35533607 [TBL] [Abstract][Full Text] [Related]
13. Novel use of nusinersen as a therapeutic bridge to onasemnogene abeparvovec-xioi in a premature neonate with type 1 spinal muscular atrophy. Ferrante L; Melendez-Zaidi A; Lindsey W; Lotze T Muscle Nerve; 2022 Aug; 66(2):E8-E10. PubMed ID: 35616550 [No Abstract] [Full Text] [Related]
14. Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios. Broekhoff TF; Sweegers CCG; Krijkamp EM; Mantel-Teeuwisse AK; Leufkens HGM; Goettsch WG; Vreman RA Value Health; 2021 Jun; 24(6):759-769. PubMed ID: 34119073 [TBL] [Abstract][Full Text] [Related]
15. Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1. Oechsel KF; Cartwright MS Muscle Nerve; 2021 Oct; 64(4):487-490. PubMed ID: 34287987 [TBL] [Abstract][Full Text] [Related]
16. Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec -A Single Centre Experience. Friese J; Geitmann S; Holzwarth D; Müller N; Sassen R; Baur U; Adler K; Kirschner J J Neuromuscul Dis; 2021; 8(2):209-216. PubMed ID: 33427694 [TBL] [Abstract][Full Text] [Related]
17. Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Monnette A; Chen E; Hong D; Bazzano A; Dixon S; Arnold WD; Shi L Orphanet J Rare Dis; 2021 Jan; 16(1):36. PubMed ID: 33472673 [TBL] [Abstract][Full Text] [Related]
18. Continued safety and long-term effectiveness of onasemnogene abeparvovec in Ohio. Waldrop MA; Chagat S; Storey M; Meyer A; Iammarino M; Reash N; Alfano L; Lowes L; Noritz G; Prochoroff A; Rossman I; Ginsberg M; Mosher K; Broomall E; Bass N; Gushue C; Kotha K; Paul G; Shell R; Tsao CY; Mendell JR; Connolly AM Neuromuscul Disord; 2024 Jan; 34():41-48. PubMed ID: 38142474 [TBL] [Abstract][Full Text] [Related]
19. Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy. Iftikhar M; Frey J; Shohan MJ; Malek S; Mousa SA Pharmacol Ther; 2021 Apr; 220():107719. PubMed ID: 33130193 [TBL] [Abstract][Full Text] [Related]
20. Short-term clinical outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy. Lee S; Lee YJ; Kong J; Ryu HW; Shim YK; Han JY; Woo H; Kim SY; Cho A; Lim BC; Chae JH Brain Dev; 2022 Apr; 44(4):287-293. PubMed ID: 35033405 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]